From the press release:
“To our knowledge, this is the first novel drug candidate that has been proposed for study in the treatment of chronic Lyme Disease post-infection in quite some time.”
Update on the Viral Genetics, Inc. (VRAL) Lyme drug program linked to previously. Reminder: IND means “Investigational new drug”, so Pre-IND is even earlier in the process.
We have recently entered into an agreement with a physician associated with one of the leading medical centers in the country to act as the “clinical lead” for this drug program. This doctor will complete the clinical portions of the pre-IND including an outline of the clinical trial protocol, as well as possibly serve as primary investigator for the planned clinical trial of our Lyme disease compound.
Many of the news stories we share have long term implications. This is progress with near term impact in terms of a diagnostics company partnering with a university to bring a test to market.
The new powerful Lyme disease diagnostic test is particularly suited to detect a chronic Lyme infection from a patient blood sample.
Scientists supported by the National Institutes of Health have published a paper on their research that sequenced genetic blueprints for 13 different strains of Borrelia burgdorferi, the bacteria that cause Lyme disease.
